International Clinical Trial: QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)

Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07113964) titled 'QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)' on Aug. 3.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: The First Affiliated Hospital with Nanjing Medical University

Condition: Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency

Intervention: Drug: QL1706 + olaparib

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: August 30, 20...